The federal government is clawing back $11.4 billion in COVID-19 funding, a move that could affect local and state public health efforts across the US.

Pembrolizumab and concurrent CRT, followed by pembrolizumab consolidation, provided long-term tumor control in previously untreated, unresectable, stage III NSCLC.

Combining savolitinib with osimertinib can reverse osimertinib resistance in patients with advanced, EGFR-mutant NSCLC, data suggest.

The objective response rate was 45.4% with SC pembrolizumab and 42.1% with IV pembrolizumab. Subcutaneous (SC) pembrolizumab appears to be non-inferior to standard intravenous (IV) pembrolizumab ...

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

The Senate has confirmed Dr Jay Bhattacharya as the new director of the NIH and Dr Marty Makary as the new commissioner of the FDA.

ICI-based combinations are the preferred first-line therapy due to their proven superiority over TKI monotherapy, many patients were not receiving them,” the researchers wrote.

(HealthDay News) — Grants from the National Institutes of Health (NIH) that were funding research on LGBTQ+ health have been canceled by the US government, alarming scientists who say the move will ...